Product Description
For Schizophrenia
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01268124 |
3253A1-1001-JA | P1 |
Completed |
Schizophrenia |
2009-04-01 |
2019-03-19 |
Treatments |
|
NCT00827489 |
3253A1-1000 | P1 |
Terminated |
Schizophrenia |
2009-04-01 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|